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Abstract
 
Background.
 
In severe congenital neutrope-
nia the maturation of myeloid progenitor cells is arrested.
The myelodysplastic syndrome and acute myeloid leuke-
mia develop in some patients with severe congenital neu-
tropenia. Abnormalities in the signal-transduction path-
ways for granulocyte colony-stimulating factor (G-CSF)
may play a part in the progression to acute myeloid leu-
kemia.
 
Methods.
 
We isolated genomic DNA and RNA from
hematopoietic cells obtained from two patients with acute
myeloid leukemia and histories of severe congenital neu-
tropenia. The nucleotide sequences encoding the cyto-
plasmic domain of the G-CSF receptor were amplified by
means of the polymerase chain reaction and sequenced.
Murine myeloid 32D.C10 cells were transfected with com-
plementary DNA encoding the wild-type or mutant G-CSF
receptors and tested for their responses to G-CSF.
 
Results.
 
Point mutations in the gene for the G-CSF
receptor were identified in both patients. The mutations, a
substitution of thymine for cytosine at the codon for
glutamine at position 718 (Gln718) in one patient and at
the codon for glutamine at position 731 (Gln731) in the
other, caused a truncation of the C-terminal cytoplasmic
region of the receptor. Both mutant and wild-type genes
for the G-CSF receptor were present in leukemic cells
from the two patients. In one patient, the mutation was
also found in the neutropenic stage, before the progres-
sion to acute myeloid leukemia. The 32D.C10 cells ex-
pressing mutant receptors had abnormally high prolifera-
tive responses but failed to mature when cultured in
G-CSF. The mutant G-CSF receptors also interfered with
terminal maturation mediated by the wild-type G-CSF re-
ceptor in the 32D.C10 cells that coexpressed the wild-
type and mutant receptors.
 
Conclusions.
 
Mutations in the gene for the G-CSF re-
ceptor that interrupt signals required for the maturation of
myeloid cells are involved in the pathogenesis of severe
congenital neutropenia and associated with the progres-
sion to acute myeloid leukemia. (N Engl J Med 1995;333:
487-93.)
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EVERE congenital neutropenia (Kostmann’s syn-
drome) comprises a heterogeneous group of disor-
ders with variable inheritance whose main features are
recurrent bacterial infections and severe neutropenia
(fewer than 200 neutrophils per cubic millimeter). The
bone marrow almost invariably shows an arrest of
granulocytic maturation at the promyelocytic or myelo-
cytic stage.
 
1-6
 
 Patients with severe congenital neutrope-
nia have an increased susceptibility to acute myeloid
leukemia.
 
7-10
 
 
An abnormal response of granulocytic progenitor
cells to granulocyte colony-stimulating factor (G-CSF)
may play a part in the pathogenesis of severe congeni-
tal neutropenia. The in vitro response to G-CSF of my-
eloid progenitor cells from patients with this disorder is
often reduced.
 
11,12
 
 Pharmacologic doses of G-CSF in-
crease the neutrophil count in the majority of patients
with severe congenital neutropenia.
 
12-14
 
 
The G-CSF receptor, a single polypeptide containing
813 amino acids,
 
15,16
 
 transduces signals that regulate
the proliferation, maturation, and survival of myeloid
progenitor cells.
 
17
 
 The cytoplasmic region proximal to
the membrane of the receptor transduces proliferative
and survival signals, whereas the distal C-terminal re-
gion transduces maturation signals and suppresses the
receptor’s proliferative signals.
 
18-20
 
 
A truncated G-CSF receptor, lacking the C-terminal
maturation domain as a consequence of a point muta-
tion, has recently been reported in a patient with se-
vere congenital neutropenia.
 
21
 
 We report here on point
mutations in the gene for the G-CSF receptor in two
patients with acute myeloid leukemia and histories of
severe congenital neutropenia. These mutations also
truncate the C-terminal cytoplasmic region of the G-CSF
receptor. The mutation in one of the patients was al-
ready present in the neutropenic phase that preceded
the development of acute myeloid leukemia. Our re-
sults suggest that the development of acute myeloid leu-
kemia in patients with severe congenital neutropenia
may involve a disruption of the maturation-signaling
function of the G-CSF receptor.
 
C
 
ASE
 
 R
 
EPORTS
 
Patient 1
 
The clinical and laboratory features of Patient 1 have been de-
scribed previously.
 
9
 
 In brief, severe congenital neutropenia was diag-
nosed in this boy when he was two years and nine months old. There
was no family history of an increased susceptibility to infection.
When the boy was 12 years old, when the infections became more
frequent and severe, G-CSF therapy was initiated; the absolute neu-
trophil count increased to 6000 per cubic millimeter. Eight months
later, while the patient was receiving G-CSF therapy, peripheral-
blood tests revealed approximately 30 percent blasts. Bone marrow
studies consistently showed a predominance of myeloblasts. Analysis
revealed a karyotype of 49,XY,
 

 
3,
 

 
der(5),t(1;5)(q21;q21),
 

 
22. The
patient died seven months later.
 
Patient 2
 
Severe congenital neutropenia was diagnosed in Patient 2 during
the first year of life, when he had severe mastoiditis. There was no
family history of hematologic disorders or an increased frequency
of infections. During the first 20 years of his life, he had frequent
episodes of pneumonitis, otitis, tonsillitis, and severe gingivitis. At
the age of 20 years, he was enrolled in a phase 1–2 study of G-CSF
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(Filgrastim) in Hannover, Germany. At that time, bone marrow
studies revealed an arrest of myelopoiesis at the promyelocytic or
myelocytic stage, with an absence of bands and segmented neutro-
phils. There were no signs of myelodysplasia, and the cellularity of
the bone marrow was normal. Treatment with G-CSF (3 
 
m
 
g per kil-
ogram of body weight per day) increased the neutrophil count to a
level above 2000 per cubic millimeter within two weeks. During the
next two years, the neutrophil count was maintained at this level
with the same dose of G-CSF, and the patient had no severe infec-
tions.
Two years after the start of G-CSF treatment, a routine bone mar-
row examination demonstrated monosomy 7 in the myeloid lineage,
but there was no sign of dysplasia or leukemia. G-CSF treatment was
immediately discontinued, but it was restarted two months later, at
the patient’s request, because of severe stomatitis. Eleven months lat-
er, the myelodysplastic syndrome (the subtype characterized by re-
fractory anemia and an excess of blasts) and thrombocytopenia de-
veloped. After an additional eight months, the patient presented with
acute myeloid leukemia (subtype M1 according to the French–Amer-
ican–British classification) and subsequently died.
 
M
 
ETHODS
 
Polymerase-Chain-Reaction Amplification
 
Genomic DNA was isolated from different cellular sources, as
described elsewhere.
 
22
 
 Total RNA was isolated from leukemic cells
from Patient 2 by the method of Chomczynski and Sacchi.
 
23
 
 RNA
was reverse-transcribed into complementary DNA (cDNA) with
the use of the reverse transcriptase of Moloney murine leukemia
virus (GIBCO-BRL, Breda, the Netherlands). Amplification with
the polymerase chain reaction (PCR) was performed as previously
described.
 
21
 
 The following primers were used: FW2, 5
 

 
TGTGATC-
ATCGTGACTCCCTT3
 

 
 (forward); FW3, 5
 

 
CTGCTGTTGTTAA-
CCTGCCTC3
 

 
 (forward); FW4, 5
 

 
CCAAGAGCAGTTTCCACCC-
AGGCC3
 

 
 (forward); FWI16, 5
 

 
ACCCTTTGTGTTCCACCAGT3
 

 
(forward); RV1, 5
 

 
CAAGATCTAGTTTACAATACTGAAG3
 

 
 (re-
verse); RV2, 5
 

 
GTAGATCTTAGTCATGGGCTTATGG3
 

 
 (reverse);
and RV3, 5
 

 
TCTCAGGGGAGATAGTGCCC3
 

 
 (reverse). The un-
derlined nucleotides indicate the introduced mismatches.
 
Nucleotide Sequencing
 
After electrophoresis on agarose gels, PCR fragments were puri-
fied with the Geneclean II kit (Bio 101, La Jolla, Calif.) and se-
quenced directly or after subcloning in the pBluescript vector (Strata-
gene, La Jolla, Calif.), with the use of the T7 Sequencing Kit
(Pharmacia P-L Biochemicals, Milwaukee).
 
Expression Vectors for G-CSF Receptor
 
A cDNA encoding a truncated G-CSF receptor (mutant DA
 
18
 
) was
cloned at the 
 
Eco
 
RI restriction site of the pBabe-puro retroviral ex-
pression vector that contains a puromycin-resistance gene,
 
24
 
 giving
rise to the pBabe-DA construct. To constitute the full-length cDNA
encoding the truncated G-CSF receptors in the two patients, PCR
fragments obtained from Patients 1 and 2 with primer sets FWI16–
RV1 and FW2–RV1, respectively, were inserted into the 
 
Hinc
 
II re-
striction site of the pBluescript vector and then cleaved with 
 
Cfr10
 
I
and 
 
Xho
 
I. The resulting 
 
Cfr10
 
I
 
 
 
and 
 
Xho
 
I fragments were used to re-
place the 
 
Cfr10
 
I–
 
Sal
 
I fragment of the pBabe-DA construct, thus cre-
ating the pBabe-1 and pBabe-2 expression vectors for Patients 1 and
2, respectively. The pLNCX expression vector containing the wild-
type G-CSF receptor cDNA (pLNCX-WT) has been described pre-
viously.
 
18
 
 
 
Cell-Line and Gene Transfection
 
A subline of the murine myeloid cell line 32D,
 
25
 
 called 32D.C10,
was fully dependent on murine interleukin-3 for proliferation and was
unresponsive to G-CSF.
 
18
 
 The 32D.C10 cells were maintained in
RPMI medium supplemented with 10 percent fetal-calf serum and 10
ng of interleukin-3 per milliliter. The expression constructs pBabe-1,
pBabe-2, and pLNCX-WT were linearized with 
 
Pvu
 
I and introduced
into the 32D.C10 cells by electroporation. After 48 hours of incuba-
tion, cells were selected with puromycin (1 
 
m
 
g per milliliter) or G418
(0.8 mg per milliliter) in semisolid culture medium containing 0.9
percent methylcellulose. Single colonies were subsequently expanded
in liquid culture for further analyses.
 
Antibodies to the G-CSF Receptor
 
Antiserum was raised by immunizing rabbits with a fusion protein
consisting of a 6-histidine–residue tag and G-CSF receptor contain-
ing the extracellular domain of the receptor from amino acid 17 to
amino acid 345. A corresponding 
 
Bam
 
HI fragment of the G-CSF
receptor cDNA was inserted into the 
 
Bam
 
HI restriction site of the
bacteria expressing vector pQE-10 (Qiagen, Düsseldorf, Germany).
A purified immunoglobulin fraction was obtained by protein A
Sepharose affinity chromatography. 
 
Western Blotting and Assays of Cell Proliferation
 
Cell lysates were prepared as described elsewhere
 
26
 
 and analyzed
by a standard method of Western blotting. Tritium-labeled–thymi-
dine uptake and long-term cell proliferation in response to G-CSF
were measured as described elsewhere.
 
18
 
 
 
Morphologic and Cytochemical Analyses
 
Cells were spun onto glass slides, and the morphologic features
were examined after May–Grünwald–Giemsa staining. Myeloperox-
idase staining was performed as described elsewhere.
 
27
 
 In each case,
at least 400 cells were examined for staining.
 
R
 
ESULTS
 
Mutations in the Gene for the G-CSF Receptor
 
The entire exon 17,
 
28
 
 which encodes the 156 amino
acids of the C-terminal cytoplasmic region, and part of
intron 16 of the G-CSF–receptor gene were amplified
by PCR from genomic DNA isolated from bone marrow
cells obtained from Patient 1 with primers FWI16 and
RV1. The PCR product was subcloned, and a pool of
18 clones was sequenced. This sequence contained a cy-
tosine-to-thymine (C-to-T) transition at nucleotide 2390
of the G-CSF receptor cDNA
 
15
 
 (Fig. 1A). Direct se-
quencing of PCR products confirmed the presence of
the point mutation (data not shown). This mutation
changes the CAA codon for glutamine at position 718
(Gln718) to the TAA stop codon, thus truncating a
C-terminal region of 96 amino acids, including the con-
served box-3 segment of the receptor’s cytoplasmic
domain
 
30
 
 (Fig. 1B).
Enzyme-restriction analysis was used to confirm the
sequencing data and to examine the ratio of mutant-
to-normal genes for the G-CSF receptor in bone mar-
row cells from Patient 1. A single mismatch was intro-
duced in primer FW4; it created a 
 
Stu
 
I restriction site
in the PCR product if the point mutation was present
in the DNA (Fig. 2A). Analysis of eight individual
clones showed that five contained the mutation (Fig.
2B). 
 
Stu
 
I digestion of the PCR product obtained from
DNA of bone marrow cells collected at various times
during the course of leukemia showed that the mutated
gene made up a minor proportion of the DNA. The mu-
tation was not detected in the liver or the spleen by 
 
Stu
 
I
digestion and nucleotide sequencing (data not shown).
These results indicate that the mutation did not occur
in the germ line.
Only RNA samples were available from leukemic
cells in peripheral blood obtained from Patient 2. Re-
verse-transcriptase PCR with primers FW2 and RV1
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was used to amplify the entire transmembrane and cy-
toplasmic domains, as well as part of the extracellular
domain, of the G-CSF–receptor cDNA. After subclon-
ing of the PCR product, nucleotide sequencing was
performed with a pool of 16 clones. A C-to-T point mu-
tation was identified at nucleotide 2429 (Fig. 1A). This
mutation, which changes the CAG codon for glutamine
at position 731 (Gln731) to the TAG stop codon, delet-
ed the 83 C-terminal amino acids of the G-CSF recep-
tor (Fig. 1B). The mutation destroys a 
 
Pvu
 
II restriction
site in the G-CSF receptor cDNA. 
 
Pvu
 
II digestion of
PCR products obtained with primers FW3 and RV2 re-
vealed transcripts of both the normal and mutated
G-CSF receptor alleles (Fig. 3). To determine whether
the point mutation was present before acute myeloid
leukemia developed in Patient 2, DNA was isolated
from a bone marrow smear prepared when the patient
was in the neutropenic phase, before the acquisition of
monosomy 7. A minor proportion of the DNA con-
tained the mutation (Fig. 3), indicating that it had aris-
en from a somatic event.
 
Transduction of Proliferative and Maturation Signals by 
Wild-Type and Mutant G-CSF Receptors
 
The function of the mutant G-CSF receptors from
the two patients was tested in murine myeloid 32D.C10
Wild type
Patient 1
Patient 2
2384
716
2437
2437
2437
733
2384
716
2384
716
CAG
Gln Pro Gln Ser Gln Ser Gly Thr Ser Asp Gln Val Leu Tyr Gly Gln Leu Leu
CCC CAA TCC CAG TCT GGC ACC AGC GAT CAG GTC CTT TAT GGG CAG CTG CTG
CAG
Gln Pro End
CCC TAA TCC CAG TCT GGC ACC AGC GAT CAG GTC CTT TAT GGG CAG CTG CTG
CAG
Gln Pro Gln Ser Gln Ser Gly Thr Ser Asp Gln Val Leu Tyr Gly End
CCC CAA TCC CAG TCT GGC ACC AGC GAT CAG GTC CTT TAT GGG TAG CTG CTG
A
 
Figure 1. Mutations in the Gene for the G-CSF Receptor in Pa-
tients 1 and 2.
Panel A shows the sequences flanking the point mutations and
the wild-type sequence. The numbers indicate the nucleotide po-
sitions (upper numbers) and amino acid positions (lower num-
bers). The point mutations are underlined. Panel B shows the
structures of the wild-type and truncated G-CSF receptors. Box-
es 1, 2, and 3 represent cytoplasmic subdomains conserved in
several members of the hematopoietin-receptor superfamily.
 
29
 
The horizontal lines in the cytoplasmic domains for Patients 1
and 2 indicate the C-terminal regions that have been deleted be-
cause of the point mutations. The numbers denote amino acid
positions.
Wild type
Patient 1
Patient 2
Extracellular
domain
Cytoplasmic
domain
Transmembrane
domain
50 amino acids
Box 1Box 2 Box 3 813
717
730
B
 
Figure 2. 
 
Stu
 
I Restriction-Enzyme Analysis of the PCR Product.
In Panel A, the point mutation in the template DNA (in the antisense orientation) is boxed. A mismatch (underlined) introduced in the
forward primer, together with the point mutation in the template DNA, creates a 
 
Stu
 
I restriction site in the PCR product. The arrows
indicate the direction of the primers. Panel B shows 
 
Stu
 
I digestion of individual clones of the PCR product obtained from leukemic
cells from Patient 1. The nondigested product (116 base pairs [bp]) was derived from normal G-CSF–receptor sequences; the digested
product (94 bp and 22 bp) was derived from the mutated allele. PCR products were separated on a 3 percent NuSieve agarose gel.
22 bp
Stu I digestion
AGG
AGGCCT
TCGGG A
AGGCC
PCR
3 5
116 bp
CCT 94 bp
116 bp —
94 bp —
22 bp —
— 396
— 344
— 298
— 220
     201
— 154
— 134
—   75
1 2 3 4 5 6 7 8 M bp
 
M denotes the molecular-size markers.
A B
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cells that were transfected with cDNA encoding the
wild-type or mutated G-CSF receptors. The expression
of the G-CSF–receptor proteins in the transfected
32D.C10 cells was examined by Western blot analysis.
The wild-type G-CSF–receptor protein had an appar-
ent molecular weight of 140,000 to 150,000, whereas
the mutant proteins from Patients 1 and 2 had a mo-
lecular weight of 115,000 to 135,000 and 120,000 to
140,000, respectively (data not shown). These varia-
tions in molecular weight were probably due to differ-
ences in protein glycosylation.
 
15
 
 
The capacities of the G-CSF receptors to transduce
proliferative signals were analyzed in assays with triti-
um-labeled thymidine. The 32D.C10 cells expressing
the wild-type receptor (32D.WT) had a dose-depend-
ent response to G-CSF and proliferated most efficient-
ly at the level of 3 ng of G-CSF per milliliter, which is
about 75 percent of the response to interleukin-3 (Fig.
4A). The 32D.C10 cells that expressed the mutant
receptors from Patient 1 (32D.1) or Patient 2 (32D.2)
had a considerably increased sensitivity to G-CSF, re-
quiring concentrations of the factor that were approx-
imately 10 times lower than the concentrations re-
quired by the 32D.WT cells for maximal proliferation.
Unlike the cells transfected with the wild-type cDNA,
the 32D.1 and 32D.2 cells had maximal responses to
G-CSF that were similar to the responses to interleu-
kin-3 (Fig. 4A).
In long-term cultures, the 32D.WT cells proliferated
transiently in medium containing G-CSF. The cells
gradually lost viability after 4 to 6 days in the medium
(Fig. 4B) and died after 12 to 14 days. In contrast, the
32D.1 and 32D.2 cells proliferated continuously and
could be maintained in G-CSF–containing culture me-
dium for at least one month.
When cultured in medium containing interleukin-3,
the 32D.WT cells had morphologic features that were
typical of those of immature myeloid cells, and 50 to 60
percent of the cells displayed weak myeloperoxidase
staining. Despite the death of substantial numbers of
cells after 8 to 12 days of culture in G-CSF–containing
medium, the surviving 32D.WT cells exhibited mor-
phologic features characteristic of terminal granulocyt-
ic maturation (Fig. 5A), and nearly all the cells showed
strong myeloperoxidase staining. In striking contrast,
G-CSF treatment of 32D.1 and 32D.2 cells induced nei-
ther morphologic changes indicative of granulocytic
maturation nor an increase in the expression of my-
eloperoxidase protein as indicated by myeloperoxidase
staining (data not shown).
 
Effect of Mutant Receptors on Granulocytic Maturation 
Mediated by the Wild-Type G-CSF Receptor
 
Because the leukemic cells from both patients ex-
pressed not only the mutated genes for the G-CSF
receptor but also the normal alleles of the gene, we
performed studies to determine whether the mutant
receptors interfere with the function of the wild-type
receptor. Two 32D.WT clones were transfected with
pBabe-puro expression vector carrying the cDNAs of
the mutant receptors from Patient 1 and Patient 2 or
only empty pBabe-puro vector (the negative control).
Expression of the wild-type and mutant G-CSF–recep-
tor proteins in single clones was verified by Western
blot analysis, and those that expressed approximate-
ly equal levels of the wild-type and mutant G-CSF–
receptor proteins were examined. Transfection of
32D.WT cells with the empty vector did not alter
G-CSF–induced proliferation and maturation (data
not shown). The 32D.WT cells coexpressing the mu-
 
Figure 3. 
 
Pvu
 
II Restriction-Enzyme Analysis of PCR Products.
Panel A shows the PCR products amplified from cDNA (top)
and genomic DNA (bottom). The relative positions of the 
 
Pvu
 
II
restriction sites and the expected sizes of the DNA fragments
(in base pairs) after 
 
Pvu
 
II digestion are indicated. The PCR
primers are also indicated. The open boxes denote the se-
quences derived from cDNA and exon 17; the sequence derived
from intron 16 is shown as a bold line. The arrows indicate the
direction of the primers. P denotes the 
 
Pvu
 
II restriction site, and
an asterisk indicates that the site was eliminated by the point
Primer FWI16 Primer RV 2
P P P*
Primer FW 3 Primer RV 2P P*
147 bp 210 bp 343 bp
44 bp 93 bp 210 bp 343 bp
100 bpA
1018 —
512 —
396     
344 —
298 —
220     
201 —
154 —
134     
75 —
553 bp
M 1 2 3 M 4 5 6 Mbp
B
 
mutation.
Panel B shows the detection of the point mutation by 
 
Pvu
 
II di-
gestion of PCR products. Amplification was performed on ge-
nomic DNA prepared from bone marrow cells obtained from
healthy persons (lanes 1 and 2) and from Patient 2 during the
neutropenic phase (lane 3), as well as on RNA isolated from nor-
mal granulocytes in peripheral blood (lanes 4 and 5) and leuke-
mic cells from Patient 2 (lane 6). PCR products were separated
on a 2 percent NuSieve agarose gel. The 553-bp fragment (ar-
row) derived from the mutant G-CSF receptor is present in lane
3 (the neutropenic phase) and in lane 6 (the leukemic phase) but
not in the lanes containing products from normal marrow. Partial
digestion does not account for the results, since there was com-
plete digestion of the other 
 
Pvu
 
II sites in the PCR products.
M denotes the molecular-size markers.
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tant receptor from Patient 1 (32D.WT-1) or Patient 2
(32D.WT-2) had increased proliferative responses to
G-CSF (Fig. 4A) and proliferated continuously in cul-
ture medium containing G-CSF alone (Fig. 4B). Both
the 32D.WT-1 cells and the 32D.WT-2 cells were un-
able to mature terminally in response to G-CSF (Fig.
5B and 5C). In fact, the responses of the 32D.WT-1
cells and the 32D.WT-2 cells to G-CSF were indistin-
guishable from the response of the 32D.1 and 32D.2
cells.
 
D
 
ISCUSSION
 
In this study, we have detected point mutations in
the gene for the G-CSF receptor in two patients with
acute myeloid leukemia and histories of severe congen-
ital neutropenia. The mutations truncate the C-termi-
nal cytoplasmic region of the receptor that participates
in the transduction of maturation signals.
 
18,19
 
 In one pa-
tient the mutation was already present in the neutro-
penic phase, before the progression to acute myeloid
leukemia. When expressed in murine 32D.C10 cells,
the truncated G-CSF receptors from the two patients
transduced stronger proliferative signals than the wild-
type receptor but were defective in inducing matura-
tion. Moreover, the mutant receptors blocked granulo-
cytic maturation even in the presence of wild-type
G-CSF receptors, presumably by forming heterodimers
with the wild-type receptors.
 
31,32
 
 Taken together, our
data suggest that disruption of the maturation-signal-
ing function of the G-CSF receptor contributes to leu-
kemogenesis.
Not all patients with severe congenital neutropenia
have mutations in the G-CSF receptor.
 
21,33,34
 
 No such
mutations corresponding to the cytoplasmic domain
were found in three patients with severe congenital
neutropenia who were members of the Swedish families
in which the disease was originally described (unpub-
lished data). However, a point mutation in the gene for
the G-CSF receptor, causing truncation of the C-termi-
nal region, has been identified in a patient with severe
congenital neutropenia and monosomy 7 but no signs
of the myelodysplastic syndrome or acute myeloid leu-
kemia (unpublished data). The mutation was detected
in myeloid cells from this patient but not in B lympho-
cytes, indicating its acquisition by a committed progen-
itor cell. Thus far, we have found mutations in the gene
for the G-CSF receptor in 4 of 14 patients with severe
congenital neutropenia; in all 4, the mutation truncated
the C-terminal region. Patients with severe congenital
neutropenia and such truncated receptors may repre-
sent a subgroup of patients in whom the neutropenia is
a preleukemic disorder.
Recombinant human G-CSF, now used frequently
in the treatment of severe congenital neutropenia,
 
12-14
 
can have favorable results. However, acute myeloid
leukemia or the myelodysplastic syndrome has devel-
oped after the administration of G-CSF in patients
with severe congenital neutropenia.
 
35-37
 
 It remains un-
certain whether G-CSF therapy contributes to the pro-
gression to acute myeloid leukemia in such patients.
Analysis of the G-CSF receptor in a large series of pa-
tients with severe congenital neutropenia will help elu-
cidate the relation among defective G-CSF–receptor
structures, the progression to acute myeloid leukemia,
 
Figure 4. G-CSF–Induced Proliferative Responses of 32D.C10 Clones Expressing Various G-CSF Receptors.
Panel A shows the response to G-CSF in comparison with the response to interleukin-3. DNA synthesis was determined by the uptake
of tritium-labeled thymidine. Data are presented as the percentage of the maximal response to 10 ng of murine interleukin-3 per mil-
liliter for each clone. Analogous results were obtained with at least three independent clones for each form of receptor. Panel B shows
the level of cell proliferation induced by G-CSF, according to the number of days in culture. Cells were cultured in medium containing
10 ng of G-CSF per milliliter. The number of viable cells was determined on the basis of trypan-blue exclusion. 32D.WT denotes cells
expressing the wild-type receptor, 32D.1 cells expressing the mutant receptor from Patient 1, 32D.2 cells expressing the mutant re-
ceptor from Patient 2, 32D.WT-1 cells expressing the wild-type receptor and mutant receptor from Patient 1, and 32D.WT-2 cells ex-
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pressing the wild-type receptor and mutant receptor from Patient 2.
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and the contribution of G-CSF therapy to leukemo-
genesis.
We are indebted to Anita Schelen, Marleen van Paassen, and Bir-
git Teichmann for excellent technical assistance; and to Dr. Hartmut
Land (Imperial Cancer Research Fund, London) for the pBabe-puro
expression vector.
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